152 related articles for article (PubMed ID: 23620766)
1. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer.
Chay WY; Chew SH; Ong WS; Busmanis I; Li X; Thung S; Ngo L; Lim SL; Lim YK; Chia YN; Koh E; Pang C; Soh LT; Wang J; Ho TH; Tay SK; Lim-Tan SK; Lim KH; Chia JW; Goh LK
PLoS One; 2013; 8(4):e61565. PubMed ID: 23620766
[TBL] [Abstract][Full Text] [Related]
2. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
[TBL] [Abstract][Full Text] [Related]
4. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
5. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
[TBL] [Abstract][Full Text] [Related]
6. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
[TBL] [Abstract][Full Text] [Related]
7. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update.
Chao WR; Lee MY; Lin WL; Koo CL; Sheu GT; Han CP
Am J Surg Pathol; 2014 Sep; 38(9):1227-34. PubMed ID: 25133707
[TBL] [Abstract][Full Text] [Related]
8. HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target.
Han CP; Hsu JD; Yao CC; Lee MY; Ruan A; Tyan YS; Yang SF; Chiang H
Histopathology; 2010 Nov; 57(5):763-4. PubMed ID: 21083606
[No Abstract] [Full Text] [Related]
9. Therapeutic options for mucinous ovarian carcinoma.
Gorringe KL; Cheasley D; Wakefield MJ; Ryland GL; Allan PE; Alsop K; Amarasinghe KC; Ananda S; Bowtell DDL; Christie M; Chiew YE; Churchman M; DeFazio A; Fereday S; Gilks CB; Gourley C; Hadley AM; Hendley J; Hunter SM; Kaufmann SH; Kennedy CJ; Köbel M; Le Page C; Li J; Lupat R; McNally OM; McAlpine JN; Pyman J; Rowley SM; Salazar C; Saunders H; Semple T; Stephens AN; Thio N; Torres MC; Traficante N; Zethoven M; Antill YC; Campbell IG; Scott CL
Gynecol Oncol; 2020 Mar; 156(3):552-560. PubMed ID: 31902686
[TBL] [Abstract][Full Text] [Related]
10. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
[TBL] [Abstract][Full Text] [Related]
11. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
12. Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification.
Nakamura A; Yamaguchi K; Minamiguchi S; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Mandai M; Matsumura N
Med Mol Morphol; 2019 Mar; 52(1):52-59. PubMed ID: 29992451
[TBL] [Abstract][Full Text] [Related]
13. HER2 expression in ovarian mucinous carcinomas in Tunisia.
Missaoui N; Abdelkarim SB; Ayachi M; Hmissa S; Yaacoubi MT
Asian Pac J Cancer Prev; 2014; 15(19):8121-5. PubMed ID: 25338994
[TBL] [Abstract][Full Text] [Related]
14. A qualitative study comparing the assay performance characteristics between the 2007 and the 2013 American Society for Clinical Oncology and College of American Pathologists HER2 scoring methods in mucinous epithelial ovarian cancer.
Chen CK; Lee MY; Lin WL; Wang YT; Han CP; Yu CP; Chao WR
Medicine (Baltimore); 2014 Dec; 93(27):e171. PubMed ID: 25501060
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive mucinous adenocarcinomas of the ovary have an expansile invasive pattern associated with a favorable prognosis.
Kim SK; Cho NH
Int J Clin Exp Pathol; 2014; 7(7):4222-30. PubMed ID: 25120802
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population.
Shan L; Ying J; Lu N
Diagn Pathol; 2013 May; 8():76. PubMed ID: 23656792
[TBL] [Abstract][Full Text] [Related]
17. HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population.
Rong L; Wang B; Guo L; Liu X; Wang B; Ying J; Xue L; Lu N
Diagn Pathol; 2020 Mar; 15(1):27. PubMed ID: 32209107
[TBL] [Abstract][Full Text] [Related]
18. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer.
Gwark SC; Lee HS; Lee Y; Lee SB; Sohn G; Kim J; Chung IY; Ko BS; Kim HJ; Son BH; Ahn JH; Jung KH; Kim SB; Lee HJ; Gong GY; Ahn SH; Lee JW
Ann Surg Oncol; 2019 Jul; 26(7):2166-2174. PubMed ID: 30977015
[TBL] [Abstract][Full Text] [Related]
20. RNF43 mutations are recurrent in Chinese patients with mucinous ovarian carcinoma but absent in other subtypes of ovarian cancer.
Zou Y; Wang F; Liu FY; Huang MZ; Li W; Yuan XQ; Huang OP; He M
Gene; 2013 Nov; 531(1):112-6. PubMed ID: 24001777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
